TA 5538
Alternative Names: TA-5538Latest Information Update: 25 May 2010
At a glance
- Originator Tanabe Seiyaku
- Class Urologics
- Mechanism of Action Neurokinin 1 antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Overactive bladder
Most Recent Events
- 12 May 2010 Discontinued - Phase-II for Overactive bladder in Europe (unspecified route)
- 12 May 2010 Discontinued - Phase-II for Overactive bladder in Japan (unspecified route)
- 01 Oct 2007 Tanabe Seiyaku Co. Ltd merged with Mitsubishi Pharma Corporation to form Mitsubishi Tanabe Pharma Corporation